Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 301, Issue 4, 2011, Pages

  Han, Yuyan ^c,f   DeMorrow, Sharon ^b,c   Invernizzi, Pietro ^e   Jing, Qing ^f   Glaser, Shannon ^b,c   Renzi, Anastasia ^c   Meng, Fanyin ^b,c,d   Venter, Julie ^c   Bernuzzi, Francesca ^e,j   White, Mellanie ^c   Francis, Heather ^b,c,d   Lleo, Ana ^e,j   Marzioni, Marco ^g   Onori, Paolo ^h   Alvaro, Domenico ⁱ   Torzilli, Guido ^e,i   Gaudio, Eugenio ^a   Alpini, Gianfranco ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c Texas A and M University   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f TONGJI UNIVERSITY   (China)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h UNIVERSITY OF L'AQUILA   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Biliary epithelium; Biliary neoplasm; Neuroendocrine regulation

Indexed keywords

ACETYLSEROTONIN METHYLTRANSFERASE; ACYLTRANSFERASE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; TUMOR BIOPSY; TUMOR XENOGRAFT;

ACETYLSEROTONIN O-METHYLTRANSFERASE; ANIMALS; APOPTOSIS; ARYLALKYLAMINE N-ACETYLTRANSFERASE; AUTOCRINE COMMUNICATION; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DOWN-REGULATION; HUMANS; LIVER NEOPLASMS; MALE; MELATONIN; MICE; MICE, NUDE; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2;

EID: 80053195476     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00118.2011     Document Type: Article

References (62)

1. Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, Onori P, Franchitto A, Coufal M, Frampton G, Alvaro D, Lee SP, Marzioni M, Benedetti A, DeMorrow S. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 68: 9184-9193, 2008.
2. Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, Marzioni M, Nuzzo G, Strazzabosco M, Stroffolini T. Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. Dig Liver Dis 43: 60-65, 2011.
3. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis 42: 490-495, 2010.
4. Arai M, Sasaki A, Saito N, Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int 55: 122-129, 2005.
5. Aust S, Thalhammer T, Humpeler S, Jager W, Klimpfinger M, Tucek G, Obrist P, Marktl W, Penner E, Ekmekcioglu C. The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia. J Pineal Res 36: 43-48, 2004.
6. Bartsch C, Bartsch H. Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol 467: 247-264, 1999.
7. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS, Kopff HS. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 59: 4693-4701, 1999.
8. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, Gentile R, Alvaro D. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol 2: 407-416, 2010.
9. Coon SL, Roseboom PH, Baler R, Weller JL, Namboodiri MA, Koonin EV, Klein DC. Pineal serotonin N-acetyltransferase: expression cloning and molecular analysis. Science 270: 1681-1683, 1995.
10. Coufal M, Invernizzi P, Gaudio E, Bernuzzi F, Frampton GA, Onori P, Franchitto A, Carpino G, Ramirez JC, Alvaro D, Marzioni M, Battisti G, Benedetti A, DeMorrow S. Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. Int J Cancer 126: 2112-2122, 2010.
11. DeMorrow S, Glaser S, Francis H, Venter J, Vaculin B, Vaculin S, Alpini G. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 282: 13098-13113, 2007.
12. Donohue SJ, Roseboom PH, Illnerova H, Weller JL, Klein DC. Human hydroxyindole-O-methyltransferase: presence of LINE-1 fragment in a cDNA clone and pineal mRNA. DNA Cell Biol 12: 715-727, 1993.
13. Esrefoglu M, Gul M, Emre MH, Polat A, Selimoglu MA. Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats. World J Gastroenterol 11: 1951-1956, 2005.
14. Fevre-Montange M, Champier J, Szathmari A, Brisson C, Reboul A, Mottolese C, Fauchon F, Claustrat B, Jouvet A. Histological features and expression of enzymes implicated in melatonin synthesis in pineal parenchymal tumours and in cultured tumoural pineal cells. Neuropathol Appl Neurobiol 34: 296-305, 2008.
15. Francis H, Glaser S, DeMorrow S, Gaudio E, Ueno Y, Venter J, Dostal D, Onori P, Franchitto A, Marzioni M, Vaculin S, Vaculin B, Katki K, Stutes M, Savage J, Alpini G. Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/ CaMK I/CREB pathway. Am J Physiol Cell Physiol 295: C499-C513, 2008.
16. Francis H, Onori P, Gaudio E, Franchitto A, DeMorrow S, Venter J, Kopriva S, Carpino G, Mancinelli R, White M, Meng F, Vetuschi A, Sferra R, Alpini G. H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res 7: 1704-1713, 2009.
17. Ganguly S, Coon SL, Klein DC. Control of melatonin synthesis in the mammalian pineal gland: the critical role of serotonin acetylation. Cell Tissue Res 309: 127-137, 2002.
18. Gonzalez A, Del Castillo-Vaquero A, Miro-Moran A, Tapia JA, Salido GM. Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. J Pineal Res 50: 250-260, 2011.
19. Grubman SA, Perrone RD, Lee DW, Murray SL, Rogers LC, Wolkoff LI, Mulberg AE, Cherington V, Jefferson DM. Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines. Am J Physiol Gastrointest Liver Physiol 266: G1060-G1070, 1994.
20. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 8: 337-346, 2009.
21. Huether G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia 49: 665-670, 1993.
22. Huether G, Messner M, Rodenbeck A, Hardeland R. Effect of continuous melatonin infusions on steady-state plasma melatonin levels in rats under near physiological conditions. J Pineal Res 24: 146-151, 1998.
23. Iuvone PM, Tosini G, Pozdeyev N, Haque R, Klein DC, Chaurasia SS. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog Retin Eye Res 24: 433-456, 2005.
24. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 49: 60-68, 2010.
25. Kanno N, Glaser S, Chowdhury U, Phinizy JL, Baiocchi L, Francis H, LeSage G, Alpini G. Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of Ca2-dependent protein kinase C-alpha. J Hepatol 34: 284-291, 2001.
26. Kirimlioglu H, Ecevit A, Yilmaz S, Kirimlioglu V, Karabulut AB. Effect of resveratrol and melatonin on oxidative stress enzymes, regeneration, and hepatocyte ultrastructure in rats subjected to 70% partial hepatectomy. Transplant Proc 40: 285-289, 2008.
27. Klagge A, Krause K, Muller K, Haag J, Fuhrer D. High-efficient nonviral transfection of the rat thyroid cell line FRTL-5. Horm Metab Res 42: 897-899, 2010.
28. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W, Meyer zum Buschenfelde KH. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1: 579-596, 1985.
29. Kokkola T, Vaittinen M, Laitinen JT. Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulation. J Pineal Res 43: 255-262, 2007.
30. Kusaka Y, Muraoka A, Tokiwa T, Sato J. [Establishment and characterization of a human cholangiocellular carcinoma cell line]. Hum Cell 1: 92-94, 1988.
31. Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat 118: 293-305, 2009.
32. Laothong U, Pinlaor P, Hiraku Y, Boonsiri P, Prakobwong S, Khoontawad J, Pinlaor S. Protective effect of melatonin against Opisthorchis viverrini-induced oxidative and nitrosative DNA damage and liver injury in hamsters. J Pineal Res 49: 271-282, 2010.
33. Lejeune M, Jaen J, Pons L, Lopez C, Salvado MT, Bosch R, Garcia M, Escriva P, Baucells J, Cugat X, Alvaro T. Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure. J Anat 212: 868-878, 2008.
34. Mancinelli R, Onori P, Gaudio E, DeMorrow S, Franchitto A, Francis H, Glaser S, Carpino G, Venter J, Alvaro D, Kopriva S, White M, Kossie A, Savage J, Alpini G. Follicle-stimulating hormone increases cholangiocyte proliferation by an autocrine mechanism via cAMP-dependent phosphorylation of ERK1/2 and Elk-1. Am J Physiol Gastrointest Liver Physiol 297: G11-G26, 2009.
35. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol 25: 503-510, 1989.
36. Naji L, Carrillo-Vico A, Guerrero JM, Calvo JR. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 74: 2227-2236, 2004.
37. Nowak K, Kuczek M, Ostropolska L, Malarska A, Wolny M, Baranowski T. The covalent structure of glyceraldehyde-phosphate dehydrogenase from human muscles. Isolation and amino acid sequences of peptides from tryptic digest. Hoppe Seylers Z Physiol Chem 356: 1181-1183, 1975.
38. Onori P, Wise C, Gaudio E, Franchitto A, Francis H, Carpino G, Lee V, Lam I, Miller T, Dostal DE, Glaser S. Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor. Int J Cancer 127: 43-54, 2010.
39. Peschke E, Wolgast S, Bazwinsky I, Ponicke K, Muhlbauer E. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res 45: 439-448, 2008.
40. Poon AM, Choy EH, Pang SF. Modulation of blood glucose by melatonin: a direct action on melatonin receptors in mouse hepatocytes. Biol Signals Recept 10: 367-379, 2001.
41. Pukkala E, Ojamo M, Rudanko SL, Stevens RG, Verkasalo PK. Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment. Cancer Causes Control 17: 573-576, 2006.
42. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12: 151-180, 1991.
43. Renzi A, Glaser S, Demorrow S, Mancinelli R, Meng F, Franchitto A, Venter J, White M, Francis H, Han Y, Alvaro D, Gaudio E, Carpino G, Onori P, Alpini G. Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors. Am J Physiol Gastrointest Liver Physiol. First published July 14, 2011;doi:10.1152/ajpgi.00206.2011.
44. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A 92: 8734-8738, 1995.
45. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 13: 1177-1185, 1994.
46. Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int 23: 692-697, 2010.
47. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177: 61-71, 1995.
48. Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid R, Wirz-Justice A, Muller-Spahn F. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 32: 59-62, 2002.
49. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 95: 825-828, 2003.
50. Schreer A, Tinson C, Sherry JP, Schirmer K. Application of Alamar blue/5-carboxyfluorescein diacetate acetoxymethyl ester as a noninvasive cell viability assay in primary hepatocytes from rainbow trout. Anal Biochem 344: 76-85, 2005.
51. Sewerynek E, Abe M, Reiter RJ, Barlow-Walden LR, Chen L, Mc- Cabe TJ, Roman LJ, Diaz-Lopez B. Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phenobarbital-treated animals. J Cell Biochem 58: 436-444, 1995.
52. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, Iwatsuki S, Herberman RB, Whiteside TL. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 52: 252-260, 1992.
53. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 7: 189-203, 2008.
54. Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes Cancer 2: 300-310, 1990.
55. Tamura EK, Fernandes PA, Marcola M, da Silveira Cruz-Machado S, Markus RP. Long-lasting priming of endothelial cells by plasma melatonin levels. PLos One 5: e13958, 2010.
56. Tan D, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ. High physiological levels of melatonin in the bile of mammals. Life Sci 65: 2523-2529, 1999.
57. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51, 1995.
58. Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett 281: 1-7, 2009.
59. von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 309: 151-162, 2002.
60. Vroman B, LaRusso NF. Development and characterization of polarized primary cultures of rat intrahepatic bile duct epithelial cells. Lab Invest 74: 303-313, 1996.
61. Woo K, Dutta AK, Patel V, Kresge C, Feranchak AP. Fluid flow induces mechanosensitive ATP release, calcium signalling and Cl- transport in biliary epithelial cells through a PKCzeta-dependent pathway. J Physiol 586: 2779-2798, 2008.
62. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 192: 147-156, 2002.